- Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
- Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
- Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
- Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
- Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
- Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
- Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
- Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
- Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
More ▼
Key statistics
On Thursday, Kronos Bio Inc (KRON:NSQ) closed at 0.98, 34.06% above the 52 week low of 0.731 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.96 |
---|---|
High | 1.00 |
Low | 0.96 |
Bid | 0.971 |
Offer | 0.997 |
Previous close | 0.96 |
Average volume | 722.26k |
---|---|
Shares outstanding | 60.10m |
Free float | 46.57m |
P/E (TTM) | -- |
Market cap | 57.69m USD |
EPS (TTM) | -1.95 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼